Newsletter Subject

Making sense of Covid data isn't easy, even with charts

From

bloombergview.com

Email Address

noreply@mail.bloombergview.com

Sent On

Sun, Sep 5, 2021 12:07 PM

Email Preheader Text

Follow Us It seems like not a day goes by without a new Covid-19 study to spark a bit of anx

[Bloomberg]( Follow Us [Get the newsletter]( It seems like not a day goes by without a new Covid-19 study to spark a bit of anxiety: [Moderna Makes Twice as Many Antibodies as Pfizer, Study Says](; [Previous Covid Prevents Delta Infection Better Than Pfizer Shot](; [South African Scientists Say New Variant May Have ‘Increased Transmissibility.’]( Despite the flood of information, humanity is still struggling to answer countless [Covid-related questions](: Are [breakthrough cases]( now the norm? Do I need a [booster shot](? Are my [antibodies waning](? Whether you Google these questions, or phone your mother to see what she thinks, the answers you receive are bound to be at best varied and at worst contradictory or even wrong. “A year and a half into the pandemic, Americans are more confused than ever about the risks they face, and that goes for experts and lay people alike,” writes Faye Flam in her [latest column](. So let’s get back to basics and begin with a simple fact: Vaccine protection is fading. But like a good pair of jeans that seem to fit better over time, this is a natural development. Vaccines still work! And your jeans still look great, even with that mustard stain! Those who got the jab earlier this year still have incredibly good protection against this virus, and even better protection against severe disease and death. You still might be wondering, how is my vaccine doing? Some of us got one shot, others two depending on the vaccine, and they’re all faring slightly differently in a delta-riddled world. In the U.K., the [ZOE COVID Study]( wanted to find out whether any of their app contributors reported a positive test result between late May — when delta became the U.K.’s dominant strain — through the end of July. The study revealed that initial protection against the virus a month after the second dose of the Pfizer/BioNTech shot was 88%. After five to six months, protection fell to 74%. For the AstraZeneca jab, there was about 77% protection a month after the second dose, which fell to 67% after four to five months. Take comfort in these numbers because it’s not as though the clock has struck midnight and protection goes poof like [Cinderella’s]( pumpkin carriage: As we continue to track and examine the efficacy of vaccines, [variants]( remain a large concern. One tweak to the virus’s genetic code can [wreak havoc]( on entire countries, causing illness and hospitalizations to soar. It seems like there’s always a new Greek letter we’re learning about. Alpha, delta and now mu, which originated in Colombia. Although this latest [variant of interest]( accounts for less than 0.1% of global Covid cases, it’s [on the rise]( in South America. In Colombia, 39% of Covid infections have been linked to the mu variant: The question is now whether we should supply already-vaccinated people in places like the U.S. with boosters or donate vaccines to prevent new variants like mu from breaking out in less economically developed parts of world. Although wealthy nations have seen their vaccinated numbers grow immensely in the past year, globally there’s still a long way to go: On the booster front, there hasn’t been much consensus, in part because President Joe Biden didn't wait to get the blessing of health authorities before setting the target date for a late September booster rollout. That plan is now in doubt, [explains]( health care columnist Max Nisen: "The desire for speed is understandable; people are scared and want to be as safe as possible. But setting a date before experts weighed in was a mistake.” Further reading on Covid-19: [We Don't Know Enough About Risks to the Vaccinated](: Faye Flam [Covid Vaccines May Become a Viable Business. That’s a Problem](: David Fickling [Biden's Rushed Booster Plan Is Already Getting Messy](: Max Nisen [Lessons From Russia’s Coronavirus Vaccine Stumble](: The Editorial Board [Vaccine Diplomacy Isn’t Working. It’s Time For a New Approach](: Clara Ferreira Marques More data from Bloomberg Opinion: [While Tesla Delays, Rivals and Drivers Move On](: Liam Denning [Higher Prices Are Here, Whether or Not You Call It Inflation](: Justin Fox [Sump Pumps and Wet Vacs Are Climate Change Must-Haves](: Tara Lachapelle This is the Theme of the Week edition of Bloomberg Opinion Today, a digest of our top commentary published every Sunday. New subscribers to the newsletter can [sign up here](. Like Bloomberg Opinion Today? [Subscribe to Bloomberg All Access and get much, much more](. You’ll receive our unmatched global news coverage and two in-depth daily newsletters, The Bloomberg Open and The Bloomberg Close. Before it’s here, it’s on the Bloomberg Terminal. Find out more about how the Terminal delivers information and analysis that financial professionals can’t find anywhere else. [Learn more](. You received this message because you are subscribed to Bloomberg's Bloomberg Opinion Today newsletter. [Unsubscribe]( | [Bloomberg.com]( | [Contact Us]( Bloomberg L.P. 731 Lexington, New York, NY, 10022

Marketing emails from bloombergview.com

View More
Sent On

21/07/2024

Sent On

20/07/2024

Sent On

19/07/2024

Sent On

18/07/2024

Sent On

17/07/2024

Sent On

16/07/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.